medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2011; 10 (1)


The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study

Jáquez QJO, García-Compean D, González GJA, Villarreal PJZ, Lavalle GFJ, Muñoz ELE, López HP, Reyes CE, Redondo VE, Flores RR, Maldonado GH

Idioma: Ingles.
Referencias bibliográficas: 39
Paginas: 56-62
Archivo PDF: 63.20 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med 2007; 120: 829-34.

  2. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30: 734-43

  3. Picardi A, D’Avola D, Gentilucci UV, Galati G, Fiori E, Spataro S, Afeltra A. Diabetes in chronic liver disease: from old concepts to new evidence. Diabetes Metab Res Rev 2006; 22: 274-83.

  4. Nielsen MF, Caumo A, Aagaard NK, Chandramouli V, Schumann WC, Landau BR, Schmitz O, at al. Contribution of defects in glucose uptake to carbohydrate intolerance in liver cirrhosis: assessment during physiological glucose and insulin concentrations. Am J Physiol Gastrointest Liver Physiol 2005; 288: 1135-43.

  5. Del Vecchio Blanco C, Gentile S, Marmo R, Carbone L, Coltorti M. Alterations of glucose metabolism in chronic liver disease. Diabetes Res Clin Pract 1990; 8: 29-36.

  6. Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19: 616-27.

  7. Petrides AS, Stanley T, Matthews DE, Vogt C, Bush AJ, Lambeth H. Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity. Hepatology 1998; 28: 141-9.

  8. El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002; 122: 1822-28.

  9. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000; 75: 355-59.

  10. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Blair SN. Alcohol intake and incidence of type 2 diabetes in men. Diabetes Care 2000; 23: 18-22.

  11. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002; 17: 677-81.

  12. Harrison SA. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 2006; 40: 68-76.

  13. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999; 22: 756-61.

  14. Bianchi G, Marchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994; 20: 119-25.

  15. Roden M. Mechanisms of Disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2006; 2: 335-48.

  16. Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther 2005; 22(Suppl. 2): 24-7.

  17. Méndez-Sánchez N, Uribe M: Obesidad. Epidemiología, Fisiopatología y Manifestaciones Clínicas. 1st. Ed. México: El Manual Moderno; 2002.

  18. Tellez-Avila FI, Sanchez-Avila F, Garcia-Saenz-de-Sicilia M, Chavez-Tapia NC, Franco-Guzman AM, Lopez-Arce G, Cerda- Contreras E, et al. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol 2008; 14: 4771-5.

  19. Nishida T, Tsuji S, Tsujii M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol 2006; 101: 70-5.

  20. American Diabetes Association: Standards of Medical Care in Diabetes-2010. Diabetes Care 2010; 33(Suppl.1): S11-S61.

  21. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh vs MELD. J Hepatol 2005; 42(Suppl. 1): 100-7.

  22. Cox D. Regression models and life tables. J Roy Statist Soc 1972; 34: 187-220.

  23. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007; 25: 883-9.

  24. Caldwell SH, Oelsner DH, Iezzoni Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization risk factors for underlying disease. Hepatology 1999; 29: 664-9.

  25. Porepa L, Ray Jg, Sanchez-Romeu P, Boot GL. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ 2010; 182: 526-31.

  26. Thomas DLM. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-9.

  27. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Blair SN. Alcohol intake and incidence of type 2 diabetes in men. Diabetes Care 2000; 23: 18-22.

  28. Adams PC, Kertesz AE, Valberg LS. Clinical presentation of hemochromatosis: changing scene. Am J Med 1991; 90: 445-9.

  29. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-23.

  30. Romero-Gomez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006; 12: 7075-80.

  31. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.

  32. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 1695-704.

  33. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8: 264-80.

  34. Amarapurkar DN, Patel ND, Kamani PM. Impact of diabetes mellitus on outcome of HCC. Ann Hepatol 2008; 7: 148-51.

  35. Adams LA.Nonalcoholic fatty liver diseases and diabetes mellitus. Endosc Res 2007; 32: 59-69.

  36. Schepke M, Appenrodt B, Heller J, Zielinski J, Sauerbruch T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver Int 2006; 26: 834-9.

  37. Moreau R, Delegue P, Pessione F, Hillaire S, Durand F, Lebrec D, Valla DC. Clinical characteristics and outcome of patients with cirrhosis refractory ascites. Liver Int 2004; 24: 457-64.

  38. Garcia-Tsao G. Bacterial infections in cirrhosis: treatment prophylaxis. J Hepatol 2005; 42(Suppl.): S85-S92.

  39. Cheruvattath R, Balan V. Infections in Patients With End-stage Liver Disease. J Clin Gastroenterol 2007; 41: 403-11.




2020     |     www.medigraphic.com